Skip to main content
Home > Week in Review > Sales & Marketing

Chronological Index of : Sales and Marketing

 Current Issue
  • Curis, Genentech, Roche sales and marketing update

    Curis Inc. (NASDAQ:CRIS), Lexington, Mass. Genentech Inc., South San Francisco, Calif. Roche (SIX:ROG; OTCQX:RHHBY), Basel, Switzerland Business: Cancer Germanys Institute for Quality and Efficiency in Health Care (…

    Published on 6/13/2016
  • Eli Lilly sales and marketing update

    Eli Lilly and Co. (NYSE:LLY), Indianapolis, Ind. Business: Cancer The U.K.s NICE issued draft guidance recommending against the use of Portrazza necitumumab from Eli Lilly to treat advanced or metastatic, squamous non-…

    Published on 6/13/2016
  • ViiV Healthcare sales and marketing update

    ViiV Healthcare, Brentford, U.K. Business: Infectious ViiV will provide 1.6 million packs of 50 mg Tivicay dolutegravir to the Ministry of Health in Botswana over the next two years as part of the Ministrys Treat All …

    Published on 6/13/2016
  • AIBioTech sales and marketing update

    American International Biotechnology LLC, Richmond, Va. Business: Diagnostic American Internationals Granger Diagnostics division launched Wound~Seq, a next-generation sequencing test to detect bacteria, fungi, …

    Published on 6/6/2016
  • Biocept sales and marketing update

    Biocept Inc. (NASDAQ:BIOC), San Diego, Calif. Business: Diagnostic Biocept launched an expression test for detecting and monitoring PD-L1 expression levels from circulating tumor cells (CTS) from blood samples.

    Published on 6/6/2016
  • Eisai sales and marketing update

    Eisai Co. Ltd. (Tokyo:4523), Tokyo, Japan Business: Neurology Eisai launched Fycompa perampanel in Japan as an adjunctive therapy for partial-onset seizures or primary generalized tonic-clonic seizures in epileptics …

    Published on 6/6/2016
  • UCB sales and marketing update

    UCB Group (Euronext:UCB), Brussels, Belgium Business: Neurology UCB launched Briviact brivaracetam in the U.S. to treat partial-onset seizures in epileptics ages 16 and older. The high affinity synaptic vesicle protein…

    Published on 6/6/2016
  • Advanced Accelerator Applications sales and marketing update

    Advanced Accelerator Applications S.A. (NASDAQ:AAAP), Saint Genis Pouilly, France Business: Cancer Advanced Accelerator launched an expanded access program (EAP) in the U.S. for Lutathera to treat inoperable, …

    Published on 4/4/2016
  • CombiMatrix, Blue Cross Blue Shield, Cigna Corp. sales and marketing update

    CombiMatrix Corp. (NASDAQ:CBMX), Irvine, Calif. Blue Cross Blue Shield, Chicago, Ill. Cigna Corp. (NYSE:CI), Bloomfield, Conn. Business: Diagnostic CombiMatrix said Cigna and three BCBS affiliates -- Premera, Life Wise …

    Published on 4/4/2016
  • Merrimack sales and marketing update

    Merrimack Pharmaceuticals Inc. (NASDAQ:MACK), Cambridge, Mass. Business: Cancer The 2016 National Comprehensive Cancer Network (NCCN) guidelines will include Merrimacks Onivyde irinotecan (MM-398) in combination with …

    Published on 4/4/2016
  • Novartis sales and marketing update

    Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland Business: Autoimmune Germanys Institute for Quality and Efficiency in Health Care (IQWiG) said an added benefit was not proven for Cosentyx secukinumab vs. …

    Published on 4/4/2016
  • Sequenom, Anthem sales and marketing update

    Sequenom Inc. (NASDAQ:SQNM), San Diego, Calif. Anthem Inc. (NYSE:ANTM), Indianapolis, Ind. Business: Diagnostic Anthem Blue Cross and Blue Shield of Connecticut, Maine and New Hampshire will cover Sequenoms noninvasive …

    Published on 4/4/2016
  • Astellas, Kotobuki, Merck sales and marketing update

    Astellas Pharma Inc. (Tokyo:4503), Tokyo, Japan Kotobuki Pharmaceutical Co., Tokyo, Japan Merck & Co. Inc. (NYSE:MRK), Whitehouse Station, N.J. Business: Endocrine/Metabolic Astellas and Merck's MSD K.K. subsidiary …

    Published on 4/28/2014
  • Chugai sales and marketing update

    Chugai Pharmaceutical Co. Ltd. (Tokyo:4519), Tokyo, Japan Business: Cancer Chugai launched Kadcyla trastuzumab emtansine in Japan to treat inoperable or recurrent HER2-positive breast cancer. Japan's National Health …

    Published on 4/28/2014
  • Cubist sales and marketing update

    Cubist Pharmaceuticals Inc. (NASDAQ:CBST), Lexington, Mass. Business: Infectious Cubist recalled one lot of Cubicin daptomycin due to the presence of particulate matter identified as glass particles found in a single …

    Published on 4/28/2014
  • Japan Tobacco, Torii sales and marketing update

    Japan Tobacco Inc. (Tokyo:2914), Tokyo, Japan Torii Pharmaceutical Co. Ltd. (Tokyo:4551), Tokyo, Japan Business: Endocrine/Metabolic Japan Tobacco and its Torii subsidiary said Torii plans to launch Riona ferric citrate…

    Published on 4/28/2014
  • MDxHealth sales and marketing update

    MDxHealth S.A. (Euronext:MDXH), Liege, Belgium Business: Diagnostic MDxHealth said U.S. healthcare PPO network Galaxy Health Network will cover MDxHealth's ConfirmMDx for Prostate Cancer test. MDxHealth said the …

    Published on 4/28/2014
  • Quest Diagnostics sales and marketing update

    Quest Diagnostics Inc. (NYSE:DGX), Madison, N.J. Business: Diagnostic Quest Diagnostics' Athena Diagnostics Inc. business unit launched in the U.S. 10 lab-developed tests based on next-generation sequencing to diagnose …

    Published on 4/28/2014
  • Response Genetics, Oregon Health & Science University sales and marketing update

    Response Genetics Inc. (NASDAQ:RGDX), Los Angeles, Calif. Oregon Health & Science University, Portland, Ore. Business: Diagnostic The university's Knight Diagnostic Institute granted Response Genetics exclusive rights …

    Published on 4/28/2014
  • Seattle Genetics, Takeda sales and marketing update

    Seattle Genetics Inc. (NASDAQ:SGEN), Bothell, Wash. Takeda Pharmaceutical Co. Ltd. (Tokyo:4502), Osaka, Japan Business: Cancer Takeda launched in Japan Adcetris brentuximab vedotin to treat patients with CD30-positive …

    Published on 4/28/2014
  • Shionogi, Viiv Healthcare sales and marketing update

    Shionogi & Co. Ltd. (Tokyo:4507), Osaka, Japan ViiV Healthcare Ltd., Brentford, U.K. Business: Infectious ViiV and Shionogi launched ViiV's Tivicay dolutegravir in Japan to treat HIV infection in combination with other …

    Published on 4/28/2014
  • Anika, J&J sales and marketing update

    Anika Therapeutics Inc. (NASDAQ:ANIK), Bedford, Mass. Johnson & Johnson (NYSE:JNJ), New Brunswick, N.J. Business: Autoimmune Anika said its U.S. commercialization partner, the DePuy Synthes Mitek Sports Medicine …

    Published on 4/21/2014
  • Dr. Reddy's, Teva sales and marketing update

    Dr. Reddy's Laboratories Ltd. (NYSE:RDY), Hyderabad, India Teva Pharmaceutical Industries Ltd. (NYSE:TEVA), Petah Tikva, Israel Business: Neurology Dr. Reddy's and Teva launched in the U.S. generic versions of …

    Published on 4/21/2014
  • Mylan sales and marketing update

    Mylan Inc. (NASDAQ:MYL), Canonsburg, Pa. Business: Endocrine/Metabolic, Generics Mylan's Mylan Pharmaceuticals Inc. subsidiary launched in the U.S. a generic version of transdermal contraceptive patch Ortho Evra …

    Published on 4/21/2014
  • Amarin, Kowa sales and marketing update

    Amarin Corp. plc (NASDAQ:AMRN), Dublin, Ireland Kowa Co. Ltd., Nagoya, Japan Business: Endocrine/Metabolic Amarin granted Kowa's Kowa Pharmaceuticals America Inc. subsidiary U.S. co-promotion rights to …

    Published on 4/7/2014

< Previous   1  2  3  4  5  6  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993